Esperion Stock Surges 57% as ARCHIMED Acquires Company for $1.1 Billion
ARCHIMED will buy Esperion and take it private for $3.16/share (+58% premium) plus up to $100M extra payouts if targets are met.
/ 2 items
ARCHIMED will buy Esperion and take it private for $3.16/share (+58% premium) plus up to $100M extra payouts if targets are met.
Esperion's cholesterol pill, NEXLETOL, is now approved in Japan through its partner, Otsuka. This major global expansion (now U.S., Europe, Japan) secures Esperion large milestone payments and tiered royalties (15%-30%) on sales.